View Item 

Show simple item record

Chronic Hepatitis B Prevalence Among Foreign‐Born and U.S.‐Born Adults in the United States, 1999‐2016
dc.contributor.authorLe, Michael H.
dc.contributor.authorYeo, Yee Hui
dc.contributor.authorCheung, Ramsey
dc.contributor.authorHenry, Linda
dc.contributor.authorLok, Anna S.
dc.contributor.authorNguyen, Mindie H.
dc.date.accessioned2020-03-17T18:30:54Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-03-17T18:30:54Z
dc.date.issued2020-02
dc.identifier.citationLe, Michael H.; Yeo, Yee Hui; Cheung, Ramsey; Henry, Linda; Lok, Anna S.; Nguyen, Mindie H. (2020). "Chronic Hepatitis B Prevalence Among Foreign‐Born and U.S.‐Born Adults in the United States, 1999‐2016." Hepatology (2): 431-443.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/154388
dc.publisherWiley Periodicals, Inc.
dc.publisherWorld Health Organization
dc.titleChronic Hepatitis B Prevalence Among Foreign‐Born and U.S.‐Born Adults in the United States, 1999‐2016
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154388/1/hep30831-sup-0001-Supinfo.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154388/2/hep30831.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154388/3/hep30831_am.pdf
dc.identifier.doi10.1002/hep.30831
dc.identifier.sourceHepatology
dc.identifier.citedreferenceChayanupatkul M, Omino R, Mittal S, Kramer JR, Richardson P, Thrift AP, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 2017; 66: 355 ‐ 362.
dc.identifier.citedreferenceHu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, et al. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009–2010. Hepatology 2013; 58: 856 ‐ 862.
dc.identifier.citedreferenceLiou IW, Nguyen MH. The cascade of care in chronic hepatitis B. Curr Hepatol Rep 2016; 15: 209 ‐ 219.
dc.identifier.citedreferenceKu KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. Dig Dis Sci 2013; 58: 3626 ‐ 3633.
dc.identifier.citedreferenceKim LH, Nguyen VG, Trinh HN, Li J, Zhang JQ, Nguyen MH. Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci 2014; 59: 2091 ‐ 2099.
dc.identifier.citedreferenceNguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, et al. Poor adherence to guidelines for treatment of chronic hepatitis B virus infection at primary care and referral practices. Clin Gastroenterol Hepatol 2019; 17: 957 ‐ 967.e7.
dc.identifier.citedreferenceKim HS, Rotundo L, Yang JD, Kim D, Kothari N, Feurdean M, et al. Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States. J Viral Hepat 2017; 24: 1052 ‐ 1066.
dc.identifier.citedreferenceWai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518 ‐ 526.
dc.identifier.citedreferenceRuhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015; 41: 65 ‐ 76.
dc.identifier.citedreferenceHepatitis B. virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40: 1 ‐ 25.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep 1984; 33: 285 ‐ 290.
dc.identifier.citedreferenceThe Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP). Diseases and Organisms. In; 2017. https://www.cdc.gov/bloodsafety/bbp/diseases-organisms.html. Accessed March 2019.
dc.identifier.citedreferenceYeo YH, Le MH, Chang ET, Henry L, Nguyen MH. Prevalence of undetectable vaccine‐induced immunity against hepatitis B virus in US adults at high risk for infection. Hepatology 2019; 69: 1385 ‐ 1397.
dc.identifier.citedreferencePollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh‐Shevrin C, et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood) 2011; 30: 1974 ‐ 1983.
dc.identifier.citedreferenceEstevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, et al. Clinical features associated with survival outcome in African‐American patients with hepatocellular carcinoma. Am J Gastroenterol 2019; 114: 80 ‐ 88.
dc.identifier.citedreferenceLiu SJ, Iqbal K, Shallow S, Speers S, Rizzo E, Gerard K, et al. Characterization of chronic hepatitis B cases among foreign‐born persons in six population‐based surveillance sites, United States 2001–2010. J Immigr Minor Health 2015; 17: 7 ‐ 12.
dc.identifier.citedreferenceGish RG, Cohen CA, Block JM, Brosgart CL, Block TM, Clary R, et al. Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology 2015; 62: 1339 ‐ 1341.
dc.identifier.citedreferenceIqbal K, Klevens RM, Kainer MA, Baumgartner J, Gerard K, Poissant T, et al. Epidemiology of acute hepatitis B in the United States from population‐based surveillance, 2006–2011. Clin Infect Dis 2015; 61: 584 ‐ 592.
dc.identifier.citedreferenceBagheri‐Jamebozorgi M, Keshavarz J, Nemati M, Mohammadi‐Hossainabad S, Rezayati MT, Nejad‐Ghaderi M, et al. The persistence of anti‐HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Hum Vaccin Immunother 2014; 10: 3731 ‐ 3736.
dc.identifier.citedreferenceMcMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22‐year follow‐up study and response to a booster dose. J Infect Dis 2009; 200: 1390 ‐ 1396.
dc.identifier.citedreferenceDepartment of Health and Human Services. Action plan for the prevention, care, and treatment of viral hepatitis: 2014–2016; 2015. https://www.hhs.gov/sites/default/files/viral-hepatitis-action-plan.pdf. Accessed March 2019.
dc.identifier.citedreferencePolaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3: 383 ‐ 403.
dc.identifier.citedreferenceWHO. Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017: 2017.
dc.identifier.citedreferenceRoberts H, Kruszon‐Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology 2016; 63: 388 ‐ 397.
dc.identifier.citedreferenceKowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin. Hepatology 2012; 56: 422 ‐ 433.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep30831-sup-0001-Supinfo.pdf
Size:
583.1KB
Format:
PDF
View/Open
Name:
hep30831.pdf
Size:
948.7KB
Format:
PDF
View/Open
Name:
hep30831_am.pdf
Size:
410.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.